News from vivus, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 31, 2011, 06:45 ET

VIVUS to Participate in Three Investor Conferences in September

VIVUS, Inc. (NASDAQ: VVUS) today announced that VIVUS management, including Leland Wilson, Chief Executive Officer; Timothy Morris, Chief Financial...

Aug 24, 2011, 17:48 ET

VIVUS Announces Closing of $45.8 Million Registered Direct Offering of Common Stock

VIVUS, Inc. (NASDAQ: VVUS) announced today that it has consummated the previously announced registered direct offering of 6,889,098 shares of...

Aug 23, 2011, 09:39 ET

VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock

VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today...

Aug 05, 2011, 07:30 ET

Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life

VIVUS, Inc. (NASDAQ: VVUS) today announced that additional data from the phase 3 QNEXA studies will be presented today during the American...

Aug 01, 2011, 16:00 ET

VIVUS Reports Second Quarter and First Six Months 2011 Financial Results

VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today...

Jul 20, 2011, 06:45 ET

Topiramate Exposure and Birth Defect Data to be Presented at the 29th International Epilepsy Congress

VIVUS, Inc. (NASDAQ: VVUS) today announced that on August 31, 2011, during the late breaking poster session at the 29th International Epilepsy...

Jun 30, 2011, 06:45 ET

VIVUS Submits New Drug Application for Avanafil for the Treatment of Erectile Dysfunction

VIVUS, Inc. (NASDAQ: VVUS) today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA)...

Jun 27, 2011, 06:45 ET

QNEXA® Data Featured at the American Diabetes Association's 71st Scientific Sessions

VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple posters were presented at the American Diabetes Association (ADA) meeting on June 26th and...

Jun 22, 2011, 06:45 ET

Multiple Presentations Featuring Long-term QNEXA® Data at the American Diabetes Association 71st Scientific Sessions

VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts have been accepted for presentation at the upcoming American Diabetes...

Jun 17, 2011, 06:45 ET

Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting

VIVUS, Inc. (Nasdaq: VVUS) today announced that the positive results from REVIVE-RP (TA-303), a phase 3 clinical trial evaluating the safety and...

Jun 14, 2011, 06:45 ET

VIVUS to Participate in Two Investor Conferences in June

VIVUS, Inc. (NASDAQ: VVUS) today announced that VIVUS management will participate in two investment conferences during the month of June....

May 31, 2011, 11:05 ET

Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity

VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented over the weekend at the European Congress on Obesity (ECO) in...

May 25, 2011, 06:00 ET

VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients

VIVUS, Inc. (NASDAQ: VVUS) today announced positive results from a phase 3, placebo-controlled clinical trial of the investigational drug avanafil...

May 20, 2011, 06:45 ET

Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity

VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at the upcoming European Congress on Obesity meeting to be...

May 17, 2011, 12:30 ET

Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting

VIVUS, Inc. (NASDAQ: VVUS) today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and...

May 13, 2011, 06:45 ET

Long-Term Data on Avanafil to be Presented at the American Urological Association Annual Meeting

VIVUS, Inc. (NASDAQ: VVUS) today announced that data on avanafil, its investigational drug candidate, will be featured in a late breaking oral...

May 02, 2011, 16:00 ET

VIVUS Reports First Quarter 2011 Financial Results

VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today...

Apr 29, 2011, 10:15 ET

VIVUS to Present at Four Upcoming Investor Conferences in May

VIVUS, Inc. (NASDAQ: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the...

Apr 11, 2011, 06:45 ET

QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities

VIVUS, Inc. (NASDAQ: VVUS) today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the...

Apr 04, 2011, 06:45 ET

Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits

VIVUS, Inc. (Nasdaq: VVUS) today announced long-term data that demonstrated patients treated with the investigational drug QNEXA® for two...